By Adriano Marchese
ANI Pharmaceuticals shares rose Friday morning after the company reported better-than-expected results in the fourth quarter and raised its guidance for the current year.
Shares traded over 10% higher at $60.08.
The specialty pharmaceutical company raised its revenue projections to a range of $756 million to $776 million for 2025, up from a previous guidance of $739 million to $759 million.
Adjusted earnings before interest, taxes, depreciation and amortization have also been revised higher to a range of $190 million to $200 million. Previously, the company expected $182 million to $192 million.
ANI also set its guidance for adjusted earnings per share of $6.12 to $6.49.
In its final quarter, total revenue rose to $190.6 million from $131.7 million, topping expectations of a more modest rise to $175.4 million, according to FactSet.
ANI swung to a loss of $10.3 million from a profit of $1.2 million. On a per-share basis, this was a loss of 55 cents, compared with a gain of 4 cents a year earlier.
Adjusted earnings, which strips out exceptional costs and one-off items, came to $1.63 a share, beating expectations of $1.44 a share.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 28, 2025 09:44 ET (14:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.